IL213930A - Production of closed linear dna - Google Patents
Production of closed linear dnaInfo
- Publication number
- IL213930A IL213930A IL213930A IL21393011A IL213930A IL 213930 A IL213930 A IL 213930A IL 213930 A IL213930 A IL 213930A IL 21393011 A IL21393011 A IL 21393011A IL 213930 A IL213930 A IL 213930A
- Authority
- IL
- Israel
- Prior art keywords
- dna
- protelomerase
- seq
- sequence
- template
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6846—Common amplification features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0901593.4A GB0901593D0 (en) | 2009-01-30 | 2009-01-30 | Production of closed linear DNA |
| PCT/GB2010/000165 WO2010086626A1 (en) | 2009-01-30 | 2010-02-01 | Production of closed linear dna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL213930A0 IL213930A0 (en) | 2011-07-31 |
| IL213930A true IL213930A (en) | 2014-08-31 |
Family
ID=40469378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL213930A IL213930A (en) | 2009-01-30 | 2011-07-05 | Production of closed linear dna |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9109250B2 (enExample) |
| EP (3) | EP3150722B1 (enExample) |
| JP (2) | JP2012516147A (enExample) |
| KR (1) | KR101926662B1 (enExample) |
| CN (2) | CN104911177A (enExample) |
| AU (1) | AU2010209532B2 (enExample) |
| BR (1) | BRPI1005683B1 (enExample) |
| CA (1) | CA2751130C (enExample) |
| DK (2) | DK2391731T3 (enExample) |
| EA (1) | EA021069B1 (enExample) |
| ES (2) | ES2400890T3 (enExample) |
| GB (1) | GB0901593D0 (enExample) |
| IL (1) | IL213930A (enExample) |
| LT (1) | LT3150722T (enExample) |
| MX (1) | MX2011007937A (enExample) |
| NZ (1) | NZ594004A (enExample) |
| SG (1) | SG173102A1 (enExample) |
| WO (1) | WO2010086626A1 (enExample) |
| ZA (1) | ZA201105013B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2026154072A1 (fr) | 2025-01-17 | 2026-07-23 | Odimma Therapeutics | Virus enveloppé pour la transfection d'acides nucléiques exogènes |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2351294B8 (es) * | 2009-07-02 | 2012-06-06 | Consejo Superior De Investigaciones Científicas (Csic) | Metodo para la replicación, amplificación, o secuenciación de un adn molde. |
| GB201013153D0 (en) * | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| US9290800B2 (en) | 2013-03-15 | 2016-03-22 | Pacific Biosciences Of California, Inc. | Targeted rolling circle amplification |
| GB201502645D0 (en) * | 2015-02-17 | 2015-04-01 | Touchlight Genetics Ltd | Method |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| RU2616279C1 (ru) * | 2015-12-28 | 2017-04-13 | Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) | Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот |
| US10077459B2 (en) | 2016-05-04 | 2018-09-18 | General Electric Company | Cell-free protein expression using rolling circle amplification product |
| CN116732145A (zh) * | 2016-08-16 | 2023-09-12 | 塔驰莱特Ip有限公司 | 闭合线性dna的生产 |
| TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| CN109971825B (zh) * | 2017-12-28 | 2020-11-10 | 南京金斯瑞生物科技有限公司 | 快速制备桑格测序模板的方法 |
| GB201805683D0 (en) * | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| CN112639110A (zh) * | 2018-06-22 | 2021-04-09 | 阿斯克肋匹奥生物制药公司 | 用于基因递送以在细胞内持续存在的载体 |
| JP7481755B2 (ja) * | 2018-11-02 | 2024-05-13 | ナイキジェン，リミテッド | 組換えパルボウイルスベクターならびにその作製および使用方法 |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| US12595501B2 (en) | 2019-06-13 | 2026-04-07 | Global Life Sciences Solutions Usa Llc | Expression of products from nucleic acid concatemers |
| WO2020255008A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| JP2022536945A (ja) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ |
| WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| CA3143634A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| CN114630675A (zh) | 2019-06-18 | 2022-06-14 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合 |
| EP3986915A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| EP3986563A1 (en) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
| CA3143627A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| EP3792367A1 (en) | 2019-09-11 | 2021-03-17 | Universität Bielefeld | Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest |
| WO2021055760A1 (en) | 2019-09-18 | 2021-03-25 | Intergalactic Therapeutics, Inc. | Synthetic dna vectors and methods of use |
| GB201915163D0 (en) | 2019-10-18 | 2019-12-04 | Univ Southampton | Cancer vaccine |
| JP7766029B2 (ja) | 2019-12-20 | 2025-11-07 | キージーン ナムローゼ フェンノートシャップ | 共有結合で閉端された核酸分子末端を使用したｎｇｓライブラリー調製 |
| EP4090750A4 (en) * | 2020-01-17 | 2024-03-13 | Asklepios Biopharmaceutical, Inc. | RECOMBINANT AAV PRODUCTION |
| CN115023503A (zh) * | 2020-01-31 | 2022-09-06 | 泰瑞斯疗法公司 | 生产闭合线性dna的方法 |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| GB202007428D0 (en) | 2020-05-19 | 2020-07-01 | Fabricnano Ltd | Polynucleotide synthesis |
| JP2023533174A (ja) | 2020-06-12 | 2023-08-02 | ユニバーシティ オブ ロチェスター | ＡＣＥ－ｔＲＮＡのコード化及び発現 |
| WO2022043400A1 (en) | 2020-08-26 | 2022-03-03 | Scancell Limited | Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen |
| JP2023543602A (ja) | 2020-10-06 | 2023-10-17 | キージーン ナムローゼ フェンノートシャップ | 標的化された配列付加 |
| EP4317424A4 (en) | 2021-03-29 | 2025-10-22 | Kaneka Corp | VECTOR, METHOD FOR PREPARING COVALENTLY BONDED CLOSED LINEAR DNA USING SAME, METHOD FOR PREPARING PARVOVIRAL VECTOR, AND PARVOVIRAL VECTOR PRODUCTION CELL |
| CN117043344A (zh) * | 2021-03-29 | 2023-11-10 | 株式会社钟化 | 载体、使用了该载体的直链状共价闭合dna的制备方法、细小病毒载体的制备方法、以及细小病毒载体产生细胞 |
| MX2023014228A (es) | 2021-06-08 | 2024-01-25 | Touchlight Ip Ltd | Vector lentiviral. |
| GB202108176D0 (en) | 2021-06-08 | 2021-07-21 | Touchlight Ip Ltd | Vector |
| US20230055381A1 (en) | 2021-06-25 | 2023-02-23 | Oxford Biomedica Solutions Llc | Adeno-associated virus packaging systems |
| EP4370151A1 (en) | 2021-07-13 | 2024-05-22 | Stonehaven Incubate AG | Composition and uses thereof |
| EP4124660A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases and methods for the production thereof |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| GB202114105D0 (en) | 2021-10-01 | 2021-11-17 | Fabricnano Ltd | Nucleotide synthesis |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| US20230323395A1 (en) | 2021-12-15 | 2023-10-12 | Homology Medicines, Inc. | Methods and compositions for the production of adeno-associated virus |
| US20250049961A1 (en) * | 2021-12-23 | 2025-02-13 | Generation Bio Co. | Scalable and high-purity cell-free synthesis of closed-ended dna vectors |
| CN114561372B (zh) * | 2022-04-27 | 2022-07-26 | 南京巨匠生物科技有限公司 | Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌 |
| EP4293101A1 (en) | 2022-06-14 | 2023-12-20 | Asklepios Biopharmaceutical, Inc. | Reactor with temperature control and method of using the same |
| CN119698477A (zh) | 2022-08-10 | 2025-03-25 | 镇江蓬勃生物科技有限公司 | 线性闭合dna的制备方法及该方法所用质粒 |
| KR20250034991A (ko) | 2022-08-16 | 2025-03-11 | 알데브론 엘엘씨 | 합성 환형 핵산 생산을 위한 무세포 방법 |
| JPWO2024058155A1 (enExample) | 2022-09-12 | 2024-03-21 | ||
| AU2023352042A1 (en) | 2022-09-29 | 2025-04-10 | Ceva Hampton Limited | Vaccine construct and uses thereof |
| EP4365303A1 (en) | 2022-11-02 | 2024-05-08 | 4basebio, S.L.U. | Purification of linear dna products |
| US20260159827A1 (en) | 2022-11-02 | 2026-06-11 | 4Basebio Uk Ltd | Purification of Linear DNA Products |
| KR102753513B1 (ko) * | 2022-11-18 | 2025-01-13 | 최낙식 | Direct RNA 추출 버퍼 및 이의 용도 |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| WO2024132094A1 (en) | 2022-12-19 | 2024-06-27 | Thermo Fisher Scientific Geneart Gmbh | Retrieval of sequence-verified nucleic acid molecules |
| ES3062031T3 (enExample) | 2023-02-01 | 2026-04-08 | 4Basebio Uk Ltd | |
| EP4410995A1 (en) * | 2023-02-01 | 2024-08-07 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases and methods for the production thereof |
| WO2024197081A1 (en) | 2023-03-20 | 2024-09-26 | Hc Bioscience, Inc. | Minimally-sized dna threads for trna therapy |
| CN116606834A (zh) * | 2023-04-10 | 2023-08-18 | 天津中合基因科技有限公司 | 多种具有切割连接活性的原端酶及其应用 |
| WO2024218190A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Generation of adeno-associated virus capsid libraries for insect cells |
| CN116732076A (zh) * | 2023-06-14 | 2023-09-12 | 通用生物(安徽)股份有限公司 | 一种闭合线性dna制备方法 |
| WO2024256842A1 (en) | 2023-06-16 | 2024-12-19 | Touchlight IP Limited | Therapeutic transfection |
| CN121816413A (zh) | 2023-08-18 | 2026-04-07 | 镇江蓬勃生物科技有限公司 | 纯化核酸分子的方法 |
| US11981936B1 (en) | 2023-09-29 | 2024-05-14 | New England Biolabs, Inc. | TelA variants, compositions, and methods |
| EP4553156A1 (en) | 2023-11-08 | 2025-05-14 | 4basebio UK Ltd | Synthetic dna production using cas nuclease |
| GB202319998D0 (en) | 2023-12-22 | 2024-02-07 | Touchlight Ip Ltd | duplexing method |
| EP4596713A1 (en) | 2024-02-05 | 2025-08-06 | 4basebio UK Ltd | Dna with enhanced resistance against exonucleases and methods for the production thereof |
| TW202548023A (zh) | 2024-03-14 | 2025-12-16 | 美商雅菲納治療公司 | 用於生產重組腺相關病毒的質體系統 |
| WO2025202929A1 (en) * | 2024-03-29 | 2025-10-02 | Pfizer Inc. | Methods for producing nucleic acids |
| US20260062728A1 (en) * | 2024-08-29 | 2026-03-05 | GE Precision Healthcare LLC | Systems and methods to improve nucleic acid synthesis and production |
| EP4729632A1 (en) | 2024-10-18 | 2026-04-22 | AskBio Inc. | Method of synthesizing dna |
| EP4786601A1 (en) | 2025-01-31 | 2026-08-05 | AskBio Inc. | Helper plasmids and uses thereof |
| WO2026163530A1 (ja) * | 2025-01-31 | 2026-08-06 | 株式会社カネカ | 転写産物の製造方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU649066B2 (en) | 1990-07-25 | 1994-05-12 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| US6953676B1 (en) | 1992-05-01 | 2005-10-11 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
| WO1994003624A1 (en) | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
| US5714320A (en) | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| DE69429038T2 (de) | 1993-07-28 | 2002-03-21 | Pe Corporation (Ny), Norwalk | Vorrichtung und Verfahren zur Nukleinsäurevervielfältigung |
| FR2732971B1 (fr) | 1995-04-13 | 1997-07-04 | Genset Sa | Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| DK0862656T3 (da) | 1995-11-21 | 2001-04-09 | Univ Yale | Unimolekylær segmentamplifikation og -detektering |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| JPH10234399A (ja) | 1997-02-28 | 1998-09-08 | Shinkinrui Kinou Kaihatsu Kenkyusho:Kk | ピシウム属菌検出用の核酸配列 |
| WO1999033559A1 (en) | 1997-12-24 | 1999-07-08 | Cepheid | Integrated fluid manipulation cartridge |
| US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
| US6054274A (en) * | 1997-11-12 | 2000-04-25 | Hewlett-Packard Company | Method of amplifying the signal of target nucleic acid sequence analyte |
| ATE346158T1 (de) | 1998-01-09 | 2006-12-15 | Univ Utah Res Found | Verfahren zur in vitro amplifikation zirkulärer dna |
| DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
| WO2000015779A2 (en) | 1998-09-15 | 2000-03-23 | Yale University | Molecular cloning using rolling circle amplification |
| WO2001004280A2 (de) * | 1999-07-08 | 2001-01-18 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze |
| AU2001250572A1 (en) | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| GB0018120D0 (en) | 2000-07-24 | 2000-09-13 | Fermentas Ab | Nuclease |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| US20030077611A1 (en) | 2001-10-24 | 2003-04-24 | Sention | Methods and systems for dynamic gene expression profiling |
| CA2412187A1 (en) | 2001-12-21 | 2003-06-21 | University Of Western Ontario | Assay for identifying modulators of borrelia telomere resolvase |
| US7081339B2 (en) | 2002-04-12 | 2006-07-25 | Primera Biosystems, Inc. | Methods for variation detection |
| AU2003251905A1 (en) | 2002-07-12 | 2004-02-02 | Affymetrix, Inc. | Synthetic tag genes |
| US20040022764A1 (en) | 2002-07-31 | 2004-02-05 | Hanan Polansky | Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
| WO2004028562A2 (de) * | 2002-09-23 | 2004-04-08 | Mologen Ag | Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze |
| US7955795B2 (en) | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
| US7452699B2 (en) | 2003-01-15 | 2008-11-18 | Dana-Farber Cancer Institute, Inc. | Amplification of DNA in a hairpin structure, and applications |
| WO2004074503A2 (en) | 2003-02-21 | 2004-09-02 | Hoser Mark J | Nucleic acid sequencing methods, kits and reagents |
| US20050244847A1 (en) | 2003-11-26 | 2005-11-03 | Eppendorf Ag | Methods and compositions for in vitro amplification of extrachromosomal nucleic acid |
| WO2006063355A2 (en) | 2004-12-11 | 2006-06-15 | Cytogenix , Inc. | Cell free biosynthesis of high-quality nucleic acid and uses thereof |
| DE602006017192D1 (de) | 2005-04-12 | 2010-11-11 | Olink Ab | Verfahren zur herstellung von oligonukleotiden |
| DE602006015633D1 (de) | 2005-04-29 | 2010-09-02 | Synthetic Genomics Inc | Amplifikation und klonierung einzelner dna-moleküle mittels rolling-circle-amplifikation |
| EP1934339B1 (en) | 2005-10-06 | 2011-12-14 | Lucigen Corporation | Thermostable viral polymerases and methods of use |
| EP1974037B1 (en) * | 2006-01-12 | 2012-03-14 | Lucigen Corporation | Linear vectors, host cells and cloning methods |
| WO2008045288A2 (en) | 2006-10-06 | 2008-04-17 | Vandalia Research, Inc. | Method for a continuous rapid thermo cycle system |
| US9598724B2 (en) * | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
| US8921072B2 (en) * | 2008-09-02 | 2014-12-30 | General Electric Compnay | Methods to generate DNA mini-circles |
| GB201013153D0 (en) * | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| US9114399B2 (en) | 2010-08-31 | 2015-08-25 | Canon U.S. Life Sciences, Inc. | System and method for serial processing of multiple nucleic acid assays |
| EP2692870A1 (en) | 2012-08-03 | 2014-02-05 | Alacris Theranostics GmbH | Method for nucleic acid amplification |
| KR102014989B1 (ko) | 2013-04-15 | 2019-08-27 | 삼성전자주식회사 | 폴리뉴클레오티드 및 그의 용도 |
-
2009
- 2009-01-30 GB GBGB0901593.4A patent/GB0901593D0/en not_active Ceased
-
2010
- 2010-02-01 EP EP16195596.8A patent/EP3150722B1/en not_active Revoked
- 2010-02-01 ES ES10702726T patent/ES2400890T3/es active Active
- 2010-02-01 DK DK10702726.0T patent/DK2391731T3/da active
- 2010-02-01 US US13/146,350 patent/US9109250B2/en active Active
- 2010-02-01 WO PCT/GB2010/000165 patent/WO2010086626A1/en not_active Ceased
- 2010-02-01 DK DK16195596.8T patent/DK3150722T3/da active
- 2010-02-01 EA EA201101141A patent/EA021069B1/ru not_active IP Right Cessation
- 2010-02-01 EP EP10702726A patent/EP2391731B1/en active Active
- 2010-02-01 AU AU2010209532A patent/AU2010209532B2/en active Active
- 2010-02-01 LT LT16195596T patent/LT3150722T/lt unknown
- 2010-02-01 SG SG2011053014A patent/SG173102A1/en unknown
- 2010-02-01 NZ NZ594004A patent/NZ594004A/xx unknown
- 2010-02-01 JP JP2011546955A patent/JP2012516147A/ja active Pending
- 2010-02-01 EP EP13152077.7A patent/EP2612925B1/en active Active
- 2010-02-01 CN CN201510314041.2A patent/CN104911177A/zh active Pending
- 2010-02-01 CN CN201080006024.8A patent/CN102301010B/zh active Active
- 2010-02-01 KR KR1020117018730A patent/KR101926662B1/ko active Active
- 2010-02-01 MX MX2011007937A patent/MX2011007937A/es active IP Right Grant
- 2010-02-01 BR BRPI1005683-1A patent/BRPI1005683B1/pt active IP Right Grant
- 2010-02-01 CA CA2751130A patent/CA2751130C/en active Active
- 2010-02-01 ES ES16195596T patent/ES2749629T3/es active Active
-
2011
- 2011-07-05 IL IL213930A patent/IL213930A/en active IP Right Grant
- 2011-07-07 ZA ZA2011/05013A patent/ZA201105013B/en unknown
-
2015
- 2015-07-30 US US14/814,258 patent/US20150329902A1/en not_active Abandoned
- 2015-09-07 JP JP2015175262A patent/JP6454243B2/ja active Active
-
2019
- 2019-02-01 US US16/265,919 patent/US11384388B2/en active Active
-
2022
- 2022-06-06 US US17/805,657 patent/US12655477B2/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060650A1 (fr) | 2015-10-08 | 2017-04-13 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2025190971A1 (fr) | 2024-03-13 | 2025-09-18 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2026154072A1 (fr) | 2025-01-17 | 2026-07-23 | Odimma Therapeutics | Virus enveloppé pour la transfection d'acides nucléiques exogènes |
| FR3171450A1 (fr) | 2025-01-17 | 2026-07-24 | Odimma Therapeutics | Virus enveloppé pour la transfection d’acides nucléiques exogènes. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220372565A1 (en) | Dna vaccines | |
| US9499847B2 (en) | Production of closed linear DNA using a palindromic sequence | |
| US12509718B2 (en) | Method of DNA synthesis | |
| HK1159693B (en) | Production of closed linear dna | |
| US20250320537A1 (en) | Synthesis of dna molecules in in vitro enzymatic systems | |
| HK1215045A1 (zh) | 用於制备闭合线状dna的体外无细胞方法的试剂盒 | |
| Xie et al. | Chlamydophila pneumoniae endonuclease IV prefers to remove mismatched 3′ ribonucleotides: Implication in proofreading mismatched 3′-terminal nucleotides in short-patch repair synthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |